Dr Reddy's gains on launch of Sumatriptan injection in US - The New Indian Express

Dr Reddy's gains on launch of Sumatriptan injection in US

Published: 26th February 2014 11:19 AM

Last Updated: 26th February 2014 11:19 AM

Dr. Reddyâ™s Laboratories shares gainedon Wednesday after it launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen® (sumatriptan succinate) 6 mg/0.5 mL in the US market on Feb. 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).

The IMITREX STATdose Pen® (sumatriptan succinate) brand and generic combined had U.S. sales of approximately $169 million MAT for the most recent twelve months ending in December 2013 according to IMS Health.

Shares of the company are trading at Rs 2,800.00, up Rs 26.1, or 0.94% at the Bombay Stock Exchange (BSE) on Wednesday at 10:14 a.m.The scrip has touched an intra-day high of Rs 2,823.00 and low of Rs 2,785.90. The total volume of shares traded at the BSE is 6,480.In the earlier session, the shares fell 0.76%, or Rs 21.25, at Rs 2,773.90.Currently, the stock is trading down 0.53% from its 52-week high of Rs 2,815.00 and above 62.74% over the 52-week low of Rs 1,720.50.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

Read More

follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook